ZNF572

Across TCGA pan-cancer cohorts, ZNF572 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF572 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF572 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF572 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SCLC, PRAD, and LUSC are the cancer types where ZNF572 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	27	view →
PRAD	DFS	Median	All	0.617	0.886	.013	6	view →
LUSC	OS	Median	II,III,IV	0.219	0.616	.029	3	view →
BLCA	DFS	Median	II,III,IV	1.000	0.329	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF572–SCLC (OS)

Open the SCLC breakdown →